British oncologists back biosimilar mAbs to treat cancer

INICIO/Políticas y legislación | Posted 03/03/2017 post-comment0 Post your comment

The British Oncology Pharmacy Association (BOPA) announced on 7 February 2017 the publication of its position statement and implementation guidelines on Biosimilar Monoclonal Antibodies.

Cancer image015

In its guideline document BOPA states that ‘oncology pharmacy teams are key to ensuring the safe, successful and timely adoption of biosimilar monoclonal antibodies (mAbs)’.

BOPA’s position is that ‘biosimilar mAbs are therapeutically equivalent to the originator molecules and can and should be used for all commissioned indications, provided pharmacovigilance safeguards are in place, e.g. branded prescribing.

Although BOPA acknowledges that ‘biosimilar mAbs cannot be automatically substituted’ they state that ‘switching from originator to biosimilar (or biosimilar to biosimilar) is acceptable and can be recommended as part of a medicines optimisation strategy’. They also believe that ‘oncology pharmacy teams have a key role in helping clinicians initiate or switch patients to biosimilar mAbs, either by directly supporting clinicians when seeing patients in clinic or indirectly by counselling patients in pharmacy, on wards or chemotherapy day units’.

The group adds that ‘oncology pharmacy teams are key to ensuring pharmacovigilance monitoring is in place to ensuring all biosimilars are prescribed by brand and batch numbers are tracked’. They add that ‘all patients switched from originator to biosimilar, or between biosimilars should be monitored and that the biosimilars SmPC (Summary of Product Characteristics) guidance on administration rates should be followed’. This they say ‘will ensure that the evidence base for safe switching is increased.’

BOPA also believes that ‘biological medicines in general are safe and well tolerated, with the potential for immunogenicity the main safety concern and that adverse reactions are likely to be batch related and not product related’.

In addition, the group states that ‘BOPA believes that the savings achieved by rapid adoption of biosimilar mAbs are an opportunity to safeguard NHS (National Health Service) budgets’ and ‘ensure that new innovative cancer medicines are affordable’. This they say will benefit patients and clinicians as well as significantly reduce NHS expenditure.

Related article
European IBD specialists support switching to biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

Source: BOPA

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
INICIO/Políticas y legislación Posted 05/11/2021
Lawsuits and US$450 million payout for price fixing and delayed generics entry
34 AA010660
INICIO/Políticas y legislación Posted 29/10/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010